Skip to main content
Smart Investors Daily
FL

NASDAQ · FLT

FLEETCOR Technologies, Inc.

Technology · Software - Infrastructure

$303.26

Down-$2.54 (-0.83%)

Updated Aug 31, 2026, 2:42 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
21.79B
P/E ratio
20.27
Dividend yield
0.00%
52-week range
— – —
Volume
334.91K
Avg. volume
456.19K

Price performance

FLT price history

1M range · 0 trading sessions · Daily adjusted prices

FLT does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest FLT news

The latest Smart Investors Daily articles mentioning FLT.

FLT research

Overview

Company profile and research snapshot.

Company profile

FLEETCOR Technologies, Inc. provides digital payment solutions for businesses to control purchases and make payments. It offers corporate payments solutions, such as accounts payable automation; Virtual Card, which provides a single-use card number for a specific amount usable within a defined timeframe; Cross-Border that is used by its customers to pay international vendors, foreign office and personnel expenses, capital expenditures, and profit repatriation and dividends; and purchasing cards and travel and entertainment cards for its customers to analyze and manage their corporate spending. The company also provides employee expense management solutions, including fuel solutions to businesses and government entities that operate vehicle fleets, as well as to oil and leasing companies, and fuel marketers; lodging solutions to businesses that have employees who travel overnight for work purposes, as well as to airlines and cruise lines to accommodate traveling crews and stranded passengers; and electronic toll payments solutions to businesses and consumers in the form of radio frequency identification tags affixed to vehicles' windshields. In addition, it offers gift card program management and processing services in plastic and digital forms that include card design, production and packaging, delivery and fulfillment, card and account management, transaction processing, promotion development and management, website design and hosting, program analytics, and card distribution channel management. Further, it provides other products consisting of payroll cards, vehicle maintenance service solution, long-haul transportation solution, prepaid food vouchers or cards, and prepaid transportation cards and vouchers. The company serves business, merchant, consumer, and payment network customers in North America, Brazil, and Internationally. The company was founded in 1986 and is headquartered in Atlanta, Georgia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$296.71
Implied upside
Analysts
FLT recent ratings
DateFirmRatingTarget
Mar 4, 2024BairdOutperform
Feb 14, 2024BMO CapitalOutperform
Feb 14, 2024UBSNeutral
Feb 8, 2024JP MorganOverweight
Feb 8, 2024RBC CapitalSector Perform
Open full forecast

News briefing

No generated briefing is available yet.

prnewswire.com · Dec 5, 2025

Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting

- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3 MORPHO trial in the post-transplant maintenance  setting and Phase 1/2 VICEROY trial in newly diagnosed disease highlight how treatment timing, sequencing and combination approaches may influence outcomes - TOKYO , Dec. 5, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that new data evaluating XOSPATA™ (gilteritinib) across FMS-like tyrosine kinase 3 mutation-positive (FLT3m+) acute myeloid leukemia (AML), including in relapsed or refractory (R/R), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting taking place from 6-9 December 2025 in Orlando, Fla. Through ongoing research with gilteritinib, Astellas is advancing the science of FLT3m+ AML and generating new evidence across the disease stages, to help improve long-term outcomes for people diagnosed with FLT3m+ AML.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.